{
    "2019-05-17": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Donâ€™t Let the Great Q1 Numbers Fool You into Buying Tilray Stock",
                "features": {
                    "keywords": [
                        "Q1 Numbers",
                        "Tilray Stock",
                        "Great"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis",
                        "stocks"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gene therapy",
                        "pricing",
                        "payment model"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure",
                "features": {
                    "keywords": [
                        "Novartis",
                        "gene therapies",
                        "US health system",
                        "pricing structure"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "GSK and Novartis liniment marketing misled Australian consumers - court",
                "features": {
                    "keywords": [
                        "GSK",
                        "Novartis",
                        "liniment marketing",
                        "Australian consumers",
                        "court"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "legal"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}